Tag: episodic migraine
Biopharma company AEON Biopharma goes public in SPAC deal
Priveterra Acquisition Corp., a special purpose acquisition company (SPAC) chaired by Robert Palmisano, has successfully completed its business combination with AEON Biopharma, a Phase 3 ... Read More
Teva’s AJOVY shows promising results in migraine prevention Phase IV study
New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries' AJOVY (fremanezumab) has led to a significant reduction in monthly ... Read More
Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting ... Read More
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients ... Read More